Native mass spectrometry: Drug discovery’s new kid on the block

Published

July 26, 2022

Native mass spectrometry: Drug discovery’s new kid on the block

Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s work, including her recent publication in Nature, highlights…

MORERelated News
Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest...
The Life Sciences Sector Successfully Toughs Out Economic Challenges
Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry...
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well...